Home › Trials › NCT06931275
Clinical trial Recruiting at 1 site Interventional Ages 2 to 95

Improving access to advanced diabetes technology for people with Type 1 Diabetes

Official title: Implementing Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

Run by T1D Exchange, United States · NCT06931275 · Data updated 2026-11-12

This study is testing a new system to help doctors prescribe advanced diabetes tools more fairly for people with Type 1 Diabetes, especially focusing on reducing differences in access for non-white patients.

Quick facts

Study typeInterventional
Ages2 Years to 95 Years
SexAll
Enrollment1178 (estimated)
SponsorT1D Exchange, United States
Academic / other
Locations2 sites (Boston, Massachusetts and 1 other locations)
StatusRecruiting
StartedAugust 13, 2024
Main results expectedJuly 30, 2027
Study endsJuly 30, 2027
Registry record updatedApril 17, 2025
Trial IDNCT06931275 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include non-Hispanic Black and Hispanic individuals aged 2 years and older with a diagnosis of Type 1 Diabetes for at least 6 months.

Probably not a fit

Patients who are already using advanced diabetes technologies at baseline will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a standardized system within electronic medical records (EMRs) to ensure equitable prescription and documentation of advanced diabetes technologies for individuals with Type 1 Diabetes (T1D). It will implement an EMR-based Best Practice Advisory (BPA) to guide healthcare providers in prescribing continuous glucose monitoring and automated insulin delivery systems. The study will assess whether this BPA can effectively reduce racial disparities in the use of these technologies and will gather insights from patients regarding their experiences and perspectives. The effectiveness will be evaluated by comparing ADT use among non-white patients at intervention centers versus matched control centers over a 12-month period.

Why it matters

Potential benefit: If successful, this approach could significantly reduce racial disparities in access to advanced diabetes technologies for patients with Type 1 Diabetes.

How similar studies have gone: Other studies have shown success in using EMR-based interventions to improve healthcare equity, making this approach promising but still relatively novel in the context of diabetes technology.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Age ≥ 2 years with an EMR diagnosis of T1D for at least 6 months at baseline and receiving care at one of six intervention centers or a matched control at another T1DX-QI center.

Inclusion Criteria:

* non-Hispanic Black and Hispanic individuals

Exclusion Criteria:

* PwT1D with evidence of use of AID at baseline

Where it's running

  • T1D Exchange
    Boston, Massachusetts, United States     Recruiting
  • T1D Exchange
    Boston, Massachusetts, United States     Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Diabetes Mellitus, Type 1 68T1D Exchange, United States 2
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.